Immunotherapies for COVID-19: Restoring the immunity could be the priority.
作者信息
Allaouchiche Bernard
机构信息
Service de Réanimation, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 69310 Pierre-Bénite, France; Université Claude Bernard Lyon1, France; Université de Lyon, VetAgro Sup, Campus Vétérinaire de Lyon, UPSP 2016.A101, Pulmonary and Cardiovascular Aggression in Sepsis, 69280 Marcy l'Étoile, France.
出版信息
Anaesth Crit Care Pain Med. 2020 Jun;39(3):385. doi: 10.1016/j.accpm.2020.05.009. Epub 2020 May 20.
Abstract
摘要
相似文献
1
Immunotherapies for COVID-19: Restoring the immunity could be the priority.针对新冠肺炎的免疫疗法：恢复免疫力可能是首要任务。
Anaesth Crit Care Pain Med. 2020 Jun;39(3):385. doi: 10.1016/j.accpm.2020.05.009. Epub 2020 May 20.
2
Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities.免疫疗法与2019冠状病毒病：挑战与机遇
J Thorac Oncol. 2020 Nov;15(11):1709-1710. doi: 10.1016/j.jtho.2020.08.015. Epub 2020 Oct 23.
3
Comparison of clinical laboratory tests between bacterial sepsis and SARS-CoV-2-associated viral sepsis.细菌脓毒症与 SARS-CoV-2 相关病毒性脓毒症的临床实验室检查比较。
Mil Med Res. 2020 Aug 4;7(1):36. doi: 10.1186/s40779-020-00267-3.
4
How to evaluate intensive care unit performance during the COVID-19 pandemic.如何评估新冠疫情期间重症监护病房的绩效。
Rev Bras Ter Intensiva. 2020 Jun;32(2):203-206. doi: 10.5935/0103-507x.20200040. Epub 2020 Jul 13.
5
Several neonates reported positive for COVID-19.几名新生儿的新冠病毒检测呈阳性。
Infect Dis (Lond). 2020 Aug;52(8):575-576. doi: 10.1080/23744235.2020.1762920. Epub 2020 May 19.
6
Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?替格瑞洛能否用于预防新型冠状病毒肺炎（COVID-19）中的脓毒症诱导的凝血病？
Clin Immunol. 2020 Jul;216:108468. doi: 10.1016/j.clim.2020.108468. Epub 2020 May 21.
7
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者：体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.
8
Important considerations regarding the future management of coronavirus (COVID-19).关于冠状病毒病（COVID-19）未来管理的重要考量因素。
Int J Surg. 2020 Jul;79:6-7. doi: 10.1016/j.ijsu.2020.04.083. Epub 2020 May 5.
9
COVID-19: Protecting Healthcare Workers is a priority.新冠疫情：保护医护人员是当务之急。
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1117. doi: 10.1017/ice.2020.148. Epub 2020 Apr 17.
10
Role of Helmet-Delivered Noninvasive Pressure Support Ventilation in COVID-19 Patients.头盔式无创压力支持通气在新冠肺炎患者中的作用
J Cardiothorac Vasc Anesth. 2020 Oct;34(10):2575-2579. doi: 10.1053/j.jvca.2020.04.060. Epub 2020 May 8.
引用本文的文献
1
A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis.SARS-CoV-2 与革兰氏阴性菌诱导的过度炎症和脓毒症的比较。
Int J Mol Sci. 2023 Oct 14;24(20):15169. doi: 10.3390/ijms242015169.
本文引用的文献
1
Immunotherapies for COVID-19: lessons learned from sepsis.新冠病毒病的免疫疗法：脓毒症的经验教训
Lancet Respir Med. 2020 Oct;8(10):946-949. doi: 10.1016/S2213-2600(20)30217-4. Epub 2020 Apr 28.
2
Tocilizumab for the treatment of severe coronavirus disease 2019.托珠单抗治疗严重 2019 冠状病毒病。
J Med Virol. 2020 Oct;92(10):2042-2049. doi: 10.1002/jmv.25964. Epub 2020 May 10.
3
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子（包括白细胞介素 6）在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
4
An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.一种在中国武汉引发肺炎疫情的新型冠状病毒：呼吁制定治疗和预防策略。
Emerg Microbes Infect. 2020 Jan 31;9(1):275-277. doi: 10.1080/22221751.2020.1723441. eCollection 2020.
Zotero 插件